DE69635017T2 - Monoklonaler antikörper reagierend mit humanem cetp und methode zur quantifizierung von humanem cetp - Google Patents

Monoklonaler antikörper reagierend mit humanem cetp und methode zur quantifizierung von humanem cetp Download PDF

Info

Publication number
DE69635017T2
DE69635017T2 DE69635017T DE69635017T DE69635017T2 DE 69635017 T2 DE69635017 T2 DE 69635017T2 DE 69635017 T DE69635017 T DE 69635017T DE 69635017 T DE69635017 T DE 69635017T DE 69635017 T2 DE69635017 T2 DE 69635017T2
Authority
DE
Germany
Prior art keywords
monoclonal antibody
labeled
immobilized
cetp
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69635017T
Other languages
German (de)
English (en)
Other versions
DE69635017D1 (de
Inventor
Masafumi Yokohama-shi KAMADA
Hiroshi Takatsuki-shi OKAMOTO
Takuya Yokohama-shi TAMATANI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Japan Tobacco Inc
Original Assignee
Japan Tobacco Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Japan Tobacco Inc filed Critical Japan Tobacco Inc
Application granted granted Critical
Publication of DE69635017D1 publication Critical patent/DE69635017D1/de
Publication of DE69635017T2 publication Critical patent/DE69635017T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/81—Packaged device or kit

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cell Biology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE69635017T 1995-05-02 1996-05-01 Monoklonaler antikörper reagierend mit humanem cetp und methode zur quantifizierung von humanem cetp Expired - Lifetime DE69635017T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP13483695 1995-05-02
JP13483695 1995-05-02
PCT/JP1996/001191 WO1996034948A1 (en) 1995-05-02 1996-05-01 Monoclonal antibody reactive with human-origin cetp and method of quantifying human-origin cetp

Publications (2)

Publication Number Publication Date
DE69635017D1 DE69635017D1 (de) 2005-09-08
DE69635017T2 true DE69635017T2 (de) 2006-06-01

Family

ID=15137605

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69635017T Expired - Lifetime DE69635017T2 (de) 1995-05-02 1996-05-01 Monoklonaler antikörper reagierend mit humanem cetp und methode zur quantifizierung von humanem cetp

Country Status (10)

Country Link
US (2) US6140474A (enExample)
EP (1) EP0825259B1 (enExample)
KR (1) KR100244573B1 (enExample)
AU (1) AU5515696A (enExample)
CA (1) CA2219947C (enExample)
DE (1) DE69635017T2 (enExample)
ES (1) ES2248808T3 (enExample)
IL (1) IL118069A (enExample)
IN (1) IN188167B (enExample)
WO (1) WO1996034948A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL118069A (en) * 1995-05-02 2000-06-01 Japan Tobacco Inc Monoclonal antibody reactive to human CETP and assay method for human CETP
US20020028469A1 (en) * 1997-11-14 2002-03-07 Burch Ronald M. Method of defining genus of chemical compound and method of designing molecules
JP2000180442A (ja) * 1998-12-15 2000-06-30 Fuji Photo Film Co Ltd 血液濾過器
US20040018577A1 (en) * 2002-07-29 2004-01-29 Emerson Campbell John Lewis Multiple hybrid immunoassay
AT500648B1 (de) * 2002-08-12 2010-03-15 Igeneon Krebs Immuntherapie Set zur behandlung von krebspatienten
WO2009101092A1 (en) * 2008-02-13 2009-08-20 Novartis Ag Farp2 and stk25 and uses thereof
MX348739B (es) * 2010-03-10 2017-06-27 F Hoffmann-La Roche Ag * Metodo para purificar soluciones de inmunoglobulina.
WO2012178058A1 (en) * 2011-06-22 2012-12-27 Indiana University Research And Technology Corporation Compositions for and methods of detecting, diagnosing and prognosing thymic cancer
WO2013075040A1 (en) * 2011-11-16 2013-05-23 The Regents Of The University Of California Cholesterol ester transfer protein (cetp) inhibitor polypeptide antibodies for prophylactic and therapeutic anti-atherosclerosis treatments
BR112016023417A2 (pt) 2014-03-21 2019-04-16 F. Hoffmann-La Roche Ag predição in vitro de meia-vida in vivo
SI3215528T1 (sl) 2014-11-06 2019-11-29 Hoffmann La Roche Variante regije Fc s spremenjeno vezavo FcRn in postopki uporabe
CN108588101B (zh) * 2018-04-27 2022-03-04 苏丹 构建同一基因不同表达载体的分子克隆方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5279540A (en) 1992-09-24 1994-01-18 Davidson Michael H Method for reducing the risk of atherosclerosis
JPH06169793A (ja) * 1992-12-02 1994-06-21 Eiken Chem Co Ltd モノクローナル抗体
JPH07128333A (ja) * 1993-11-09 1995-05-19 Nippon Koutai Kenkyusho:Kk コレステリルエステル転送蛋白の免疫測定法
IL118069A (en) * 1995-05-02 2000-06-01 Japan Tobacco Inc Monoclonal antibody reactive to human CETP and assay method for human CETP

Also Published As

Publication number Publication date
IL118069A0 (en) 1996-08-04
AU5515696A (en) 1996-11-21
IN188167B (enExample) 2002-08-31
EP0825259A1 (en) 1998-02-25
US6410020B1 (en) 2002-06-25
IL118069A (en) 2000-06-01
EP0825259B1 (en) 2005-08-03
ES2248808T3 (es) 2006-03-16
EP0825259A4 (en) 2001-04-25
WO1996034948A1 (en) 1996-11-07
CA2219947C (en) 2007-02-13
KR100244573B1 (ko) 2000-02-15
KR19990008283A (ko) 1999-01-25
US6140474A (en) 2000-10-31
DE69635017D1 (de) 2005-09-08
CA2219947A1 (en) 1996-11-07

Similar Documents

Publication Publication Date Title
DE3888224T2 (de) Bestimmung vom Tumornekrosefaktor; monoklonaler Antikörper und Zusammensetzung.
EP0158599B1 (de) Neue monoklonale Antikörper und Hybridoma-Zellen, Verfahren zu ihrer Herstellung und ihre Anwendungen
DE3689734T2 (de) Gereinigter immunoglobulinbezüglicher Faktor, monoklonale Antikörper, Hybridoma-Zellinien, Verfahren und Verwendungen.
DE69635017T2 (de) Monoklonaler antikörper reagierend mit humanem cetp und methode zur quantifizierung von humanem cetp
DE60128452T2 (de) Monoklonale antikörper gegen den menschlichen ldl-rezeptor, deren herstellung und verwendung
DE3876124T2 (de) Immunoassay fuer thrombomodulin.
DE68921374T2 (de) Monoklonaler Antikörper gegen menschliche Mangan-Superoxiddismutase, Verfahren zu dessen Herstellung, Testreagens, Kit und Testmethode unter Verwendung desselben, Verfahren zur Diagnose von menschlichem Eierstockkrebs und von Herzinfarkt.
AU2001241002A1 (en) Monoclonal antibodies to the human LDL receptor, their production and use
Schatz et al. Polyclonal nature of islet cell antibodies in insulin-dependent diabetes
DE3850993T2 (de) Monoklonaler Antikörper spezifisch gegen humane Pankreas-Phospholipase-A2.
DE68911574T2 (de) Reagenzsystem zur Bestimmung des Komplexes des menschlichen Plasminogenaktivator-Inhibitors und des menschlichen Gewebeplasminogenaktivators und Testsatz dafür.
EP0589982B1 (de) Monoklonale antikörper gegen das humane tnf-bindende protein i (tnf-bp i)
JP3580948B2 (ja) ヒト由来ｃｅｔｐに反応性を有するモノクローナル抗体及びヒト由来ｃｅｔｐの定量方法
DE19653358A1 (de) Immunoassay zum Nachweis von MIA
DE69114361T2 (de) Monoklonaler Antikörper, der Membran-Phopholipase A2 erkennt und Immuntest für Membran-Phospholipase A2.
DE4120213C2 (de) Monoklonale Antikörper gegen das TNF-bindende Protein I (TNF-BP I)
DE60036452T2 (de) Monoklonaler anti-uracil antikörper
DE3784502T2 (de) Monoklonaler antikoerper, verfahren zu seiner herstellung und diagnostikum, das ihn enthaelt.
EP0420151B1 (en) Anti-rhodopsin monoclonal antibody and use thereof
WO2002026831A1 (de) Monoklonale antikörper gegen humanes cathepsin w
DE19839736A1 (de) Humane monoklonale Antikörper gegen Inselzellantigen IA-2
DE19547416A1 (de) Verfahren zur Herstellung von monoklonalen Antikörpern gegen Proteasom und die Verwendung der Antikörper zum Nachweis und zur Isolierung des Proteasoms
HK1055750B (en) Monoclonal antibodies to the human ldl receptor, their production and use

Legal Events

Date Code Title Description
8364 No opposition during term of opposition